N-(3-ethylphenyl)-3-(trifluoromethyl)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-ethylphenyl)-3-(trifluoromethyl)benzamide
• 化学式: C₁₆H₁₄F₃NO
• 分子量: 293.28
• InChiKey: BPXZXCQFKJIWHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF
  申请人：Xiamen University

  公开号：US20200165246A1

  公开（公告）日：2020-05-28

  A type of substituted penta-fused hexa-heterocyclic compounds having selective inhibition for PIKfyve kinase, a pharmaceutically acceptable salt and pharmaceutically acceptable solvate thereof, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with PIKfyve in vivo, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.

  一种替代的五重融合六元杂环化合物，具有对PIKfyve激酶的选择性抑制作用，其药学上可接受的盐及其药学上可接受的溶剂，其制备方法，包括这些化合物的药物组合物，以及在制备用于预防或治疗与PIKfyve相关疾病的药物中使用这些化合物，特别是在制备用于预防或治疗肿瘤生长和转移的药物中。
• Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof
  申请人：Xiamen University

  公开号：US11352354B2

  公开（公告）日：2022-06-07

  A type of substituted penta-fused hexa-heterocyclic compounds having selective inhibition for PIKfyve kinase, a pharmaceutically acceptable salt and pharmaceutically acceptable solvate thereof, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with PIKfyve in vivo, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.

  一种对PIKfyve激酶具有选择性抑制作用的取代五融合六六环化合物、其药学上可接受的盐和药学上可接受的溶液、其制备方法、包含这些化合物的药物组合物，以及这些化合物在制造预防或治疗体内PIKfyve相关疾病的药物中的用途，特别是在制造预防或治疗肿瘤生长和转移的药物中的用途。
• ARYL AMINE SUBSTITUTED PYRIMIDINE AND QUINAZOLINE AND THEIR USE AS ANTICANCER DRUGS
  申请人：National Yang-Ming University

  公开号：US20150246891A1

  公开（公告）日：2015-09-03

  A series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma and human lung adenocarcinoma were evaluated.
• US9394261B2
  申请人：——

  公开号：US9394261B2

  公开（公告）日：2016-07-19